CRISPR

CRISPR2-etsrp

ID

ZDB-CRISPR-200423-3

Name

CRISPR2-etsrp

Previous Names

None

Target

etsrp (1)

Sequence

5' - GGGAAAGGCCCAAGTCACAG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

The PAM site was "AGG" at the 3' end.

Genome Resources

None

Target Location

Constructs

Genomic Features

Genomic Feature	Affected Genomic Regions
ci32Gt	etsrp
ci33	etsrp
ci48Gt	etsrp

Expression

Gene expression in Wild Types + CRISPR2-etsrp

No data available

Phenotype

Phenotype resulting from CRISPR2-etsrp

No data available

Phenotype of all Fish created by or utilizing CRISPR2-etsrp

Phenotype	Fish	Conditions	Figures
common cardinal vein etsrp expression decreased amount, abnormal	etsrp^ci32Gt/+; nkuasgfp1aTg	standard conditions	Fig. 7 from Chestnut et al., 2019
intersegmental vessel EGFP expression decreased amount, abnormal	etsrp^ci32Gt/+; nkuasgfp1aTg	standard conditions	Fig. 3 from Chestnut et al., 2020
intermediate cell mass of mesoderm etsrp expression decreased amount, abnormal	etsrp^ci32Gt/+; nkuasgfp1aTg	standard conditions	Fig. 7 from Chestnut et al., 2019
anterior lateral plate mesoderm etsrp expression decreased amount, abnormal	etsrp^ci32Gt/+; nkuasgfp1aTg	standard conditions	Fig. 7 from Chestnut et al., 2019
dorsal aorta etsrp expression decreased amount, abnormal	etsrp^ci32Gt/+; nkuasgfp1aTg	standard conditions	Fig. 7 from Chestnut et al., 2019
skeletal muscle cell EGFP expression increased amount, abnormal	etsrp^ci32Gt/+; nkuasgfp1aTg	standard conditions	Fig. 3 from Chestnut et al., 2020
cranial vasculature etsrp expression decreased amount, abnormal	etsrp^ci32Gt/+; nkuasgfp1aTg	standard conditions	Fig. 7 from Chestnut et al., 2019
skeletal muscle cell differentiation increased occurrence, abnormal	etsrp^ci32Gt/+; nkuasgfp1aTg + MO1-etsrp + MO2-etsrp	standard conditions	Fig. 3 from Chestnut et al., 2020
skeletal muscle cell differentiation decreased occurrence, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	chemical treatment by environment: SU5402	Fig. 6 from Chestnut et al., 2020
intermediate cell mass of mesoderm etsrp expression decreased distribution, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 7 from Chestnut et al., 2019
intersegmental vessel absent, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 8 from Chestnut et al., 2019
blood vessel endothelial cell differentiation decreased occurrence, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 3 , Fig. 4 , Fig. 5 from Chestnut et al., 2020
anterior lateral plate mesoderm etsrp expression absent, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 7 from Chestnut et al., 2019
skeletal muscle cell EGFP expression increased amount, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 3 from Chestnut et al., 2020
intersegmental vessel decreased amount, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 8 from Chestnut et al., 2019
common cardinal vein EGFP expression absent, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 8 from Chestnut et al., 2019
common cardinal vein etsrp expression absent, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 7 from Chestnut et al., 2019
intersegmental vessel EGFP expression decreased distribution, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 8 from Chestnut et al., 2019
cranial vasculature EGFP expression decreased amount, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 8 from Chestnut et al., 2019
skeletal muscle cell differentiation increased occurrence, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 3 , Fig. 4 , Fig. 5 from Chestnut et al., 2020
intersegmental vessel EGFP expression absent, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 8 from Chestnut et al., 2019
cranial vasculature EGFP expression decreased distribution, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 8 from Chestnut et al., 2019
blood vessel development disrupted, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 8 , Fig. 9 from Chestnut et al., 2019
dorsal aorta etsrp expression absent, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 7 from Chestnut et al., 2019
cranial vasculature etsrp expression decreased distribution, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 7 from Chestnut et al., 2019
lateral plate mesoderm apoptotic process increased occurrence, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 4 , Fig. 5 from Chestnut et al., 2020
intermediate cell mass of mesoderm etsrp expression decreased amount, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 7 from Chestnut et al., 2019
cranial vasculature etsrp expression decreased amount, abnormal	etsrp^{ci32Gt/ci32Gt}; nkuasgfp1aTg	standard conditions	Fig. 7 from Chestnut et al., 2019
vascular endothelium normal object quality, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	standard conditions	Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression decreased amount, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium damaged, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression spatial pattern, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression decreased amount, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression spatial pattern, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
skeletal muscle cell differentiation decreased occurrence, abnormal	etsrp^ci32Gt/+; nkuasgfp1aTg; w32Tg	heat shock	Fig. 6 from Chestnut et al., 2020
vascular endothelium damaged, abnormal	etsrp^{ci32Gt/ci32Gt}; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression decreased amount, abnormal	etsrp^{ci32Gt/ci32Gt}; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression spatial pattern, abnormal	etsrp^{ci32Gt/ci32Gt}; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression spatial pattern, abnormal	etsrp^{ci32Gt/ci32Gt}; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression spatial pattern, abnormal	etsrp^{ci32Gt/ci32Gt}; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	standard conditions	Fig. 4 from Metikala et al., 2022
vascular endothelium etsrp expression decreased amount, abnormal	etsrp^{ci32Gt/ci32Gt}; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression decreased amount, abnormal	etsrp^{ci32Gt/ci32Gt}; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	standard conditions	Fig. 4 from Metikala et al., 2022
vascular endothelium morphogenesis of a branching structure decreased process quality, abnormal	etsrp^{ci32Gt/ci32Gt}; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	standard conditions	Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression spatial pattern, abnormal	etsrp^{ci32Gt/ci32Gt}; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	standard conditions	Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression decreased amount, abnormal	etsrp^{ci32Gt/ci32Gt}; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium regeneration decreased process quality, abnormal	etsrp^{ci32Gt/ci32Gt}; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression decreased amount, abnormal	etsrp^{ci32Gt/ci32Gt}; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg	standard conditions	Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression spatial pattern, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	standard conditions	Fig. 4 from Metikala et al., 2022
vascular endothelium morphogenesis of a branching structure decreased process quality, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	standard conditions	Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression decreased amount, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	standard conditions	Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression decreased amount, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium regeneration decreased process quality, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium damaged, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression spatial pattern, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression decreased amount, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression spatial pattern, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression spatial pattern, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	standard conditions	Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression decreased amount, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	standard conditions	Fig. 4 from Metikala et al., 2022
skeletal muscle cell differentiation decreased occurrence, abnormal	etsrp^ci32Gt/+; c264Tg; pd1Tg	heat shock	Fig. 6 from Chestnut et al., 2020

Citations